# Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

> **NCT03073694** · PHASE2 · UNKNOWN · sponsor: **University of Kansas Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Cancer, Appendiceal
- ColoRectal Cancer

## Interventions

- **DRUG:** Mitomycin c
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT03073694
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-14
- **Primary completion:** 2024-07
- **Final completion:** 2025-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03073694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03073694, "Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03073694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*